Go Pro

STERIS (STE) Stock Forecast & Price Target

STERIS logo
$229.87 -3.41 (-1.46%)
As of 03:58 PM Eastern

STERIS - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for STERIS in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for STE.

Consensus Price Target

$271.33
18.04% Upside
According to the 4 analysts' twelve-month price targets for STERIS, the average price target is $271.33. The highest price target for STE is $275.00, while the lowest price target for STE is $269.00. The average price target represents a forecasted upside of 18.04% from the current price of $229.87.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for STE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for STERIS and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STE Analyst Ratings Over Time

TypeCurrent Forecast
8/17/25 to 8/17/26
1 Month Ago
7/18/25 to 7/18/26
3 Months Ago
5/19/25 to 5/19/26
1 Year Ago
8/17/24 to 8/17/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$271.33$278.00$275.67$273.50
Forecasted Upside18.04% Upside27.72% Upside28.55% Upside11.40% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

STE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

STERIS Stock vs. The Competition

TypeSTERISHealthcare CompaniesBroader Market
Consensus Rating Score
2.75
2.29
2.53
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside18.04% Upside796.16% Upside12.16% Upside
News Sentiment Rating
Positive News

See Recent STE News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/7/2026
UBS Group AG logo
UBS Group
4 of 5 stars
Patrick Wood
Not Rated
Lower TargetBuy$275.00 ➝ $270.00+13.59%
8/7/2026
Piper Sandler logo
Piper Sandler
2 of 5 stars
Jason Bednar
Jason Bednar
2 of 5 stars
Reiterated RatingOverweight$270.00 ➝ $275.00+16.19%
5/27/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 DowngradeHold (C+)Hold (C)
5/13/2026Lower TargetOverweight$291.00 ➝ $269.00+27.55%
8/8/2025Boost TargetOverweight$276.00 ➝ $295.00+22.18%
5/29/2025Initiated CoverageHold$263.00+7.33%
5/16/2025 Reiterated RatingOutperform
5/16/2025Boost TargetMarket Outperform$265.00 ➝ $280.00+11.84%
5/15/2025Reiterated RatingOverweight$250.00 ➝ $250.00+1.92%
4/7/2025Reiterated RatingHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:33 PM ET.


Should I Buy STERIS Stock? STE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 17, 2026. Please send any questions or comments about these STERIS pros and cons to contact@marketbeat.com.

STERIS
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in STERIS plc:

  • The company recently reported earnings per share (EPS) of $2.83, which, while slightly below expectations, reflects a solid performance in a competitive market.
  • STERIS plc has shown consistent revenue growth, with a year-over-year increase of approximately 6.7%, indicating strong demand for its medical equipment and services.
  • The current stock price is around $270, which is supported by a consensus target price of $277.25, suggesting potential for appreciation.
  • STERIS plc has a healthy net margin of 13.18% and a return on equity of 14.15%, demonstrating effective management and profitability.
  • The company has recently increased its quarterly dividend to $0.69 per share, reflecting a commitment to returning value to shareholders, with a yield of about 1.2%.

STERIS
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in STERIS plc for these reasons:

  • The company missed EPS estimates by $0.03, which may raise concerns about its ability to meet future expectations.
  • Despite revenue growth, the overall market for medical equipment can be volatile, influenced by regulatory changes and economic conditions.
  • Analysts have recently downgraded the stock rating from "strong-buy" to "buy," which may indicate a shift in market sentiment.
  • STERIS plc's payout ratio is around 31.78%, which, while sustainable, may limit the company's ability to reinvest in growth opportunities.
  • Insider selling activity, including recent transactions by the CEO, could signal a lack of confidence in the stock's short-term performance.

STE Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for STERIS is $271.33, with a high forecast of $275.00 and a low forecast of $269.00.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last year. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STE shares.

According to analysts, STERIS's stock has a predicted upside of 18.04% based on their 12-month stock forecasts.

Over the previous 90 days, STERIS's stock had 1 downgrade by analysts.

STERIS has been rated by research analysts at Piper Sandler, UBS Group, and Weiss Ratings in the past 90 days.

Analysts like STERIS more than other "healthcare" companies. The consensus rating for STERIS is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how STE compares to other companies.

Brokerages With STERIS Recommendations


This page (NYSE:STE) was last updated on 8/17/2026 by MarketBeat.com Staff.
From Our Partners